NovaBay Pharma (NBY) Stock Statistics & Valuation Metrics

NovaBay Pharma has a market cap or net worth of $46.33M. The enterprise value is $39.15M.

NovaBay Pharma has 26,625,029 shares outstanding. The number of shares has decreased by -2.65% in one year.

NovaBay Pharma’s return on equity (ROE) is 0.97 and return on invested capital (ROIC) is -90.49%.

The current PE Ratio of NovaBay Pharma is ―. NovaBay Pharma’s PEG ratio is -0.01.

In the last 12 months, NovaBay Pharma had revenue of 0.00 and earned -22.14M in profits. Earnings per share was -3.80.

In the last 12 months, operating cash flow was -8.39M and capital expenditures 0.00, giving a free cash flow of -8.39M billion.

NovaBay Pharma pays an annual dividend of $0.8, resulting in a dividend yield of ―

NovaBay Pharma upcoming earnings date is May 7, 2026, After Close (Confirmed).

NovaBay Pharma as a current ratio of 7.60, with Debt / Equity ratio of -3.40%

In the past 12 months, NovaBay Pharma has paid 0.00 in taxes.

NovaBay Pharma EV to EBITDA ratio is -21.08, with an EV/FCF ratio of -18.62.

NovaBay Pharma has $7.96M in cash and marketable securities with $776.00K in debt, giving a net cash position of $7.18M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for NovaBay Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―